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Abstract
Background: Immunodeficient mouse models that accept human cell and tissue grafts can contribute greater
knowledge to human stem cell research. In this technical report, we used biomaterial implants seeded with
genetically engineered stromal cells to create several unique microenvironments in a single mouse. The scope of
study was focused on human CD34 hematopoietic stem/progenitor cell (HSPC) engraftment and differentiation
within the engineered microenvironment.
Results: A mouse model system was created using subdermal implant sites that overexpressed a specific human
cytokines (Vascular Endothelial Growth Factor A (hVEGFa), Stromal Derived Factor 1 Alpha (hSDF1a), or Tumor
Necrosis Factor Alpha (hTNFa)) by stromal cells in a three-dimensional biomaterial matrix. The systemic exposure
of locally overexpressed cytokines was minimized by controlling the growth of stromal cells, which led to autonomous
local, concentrated sites in a single mouse for study. This biomaterial implant approach allowed for the local analysis of
each cytokine on hematopoietic stem cell recruitment, engraftment and differentiation in four different tissue
microenvironments in the same host. The engineered factors were validated to have bioactive effects on human
CD34+ hematopoietic progenitor cell differentiation.
Conclusions: This model system can serve as a new platform for the study of multiple human proteins and their
local effects on hematopoietic cell biology for in vivo validation studies.
Keywords: Genetically engineered stroma, Chimeric mouse model, Human hematopoietic stem and progenitor
cells, Implantable microenvironments, Scaffolds, Bone marrow stromal cells
Background
Immunodeficient mice lack immune cell activity and do
not acutely reject xenogenic cells and tissues [1, 2]. These
mouse strains have been an enabling tool for understanding
human cell growth and functions in the context of living
systems [3–6]. In particular, these mouse models have
greatly advanced functional characterization of human
hematopoietic stem and progenitor cells (HSPCs) [7, 8].
Human HSPCs can be intravenously injected and engrafted
into a host immunodeficient mouse to form a chimeric
hematopoietic system. These experiments have helped to
identify and validate factors that control human HSPCs
migration, engraftment, self-renewal, and differentiation in
mice for mechanistic and therapeutic purposes [9]. Yet,
there still remain critical areas to improve these immuno-
deficient mouse models to better model human HSPCs
[10]. For example, human HSPCs do not engraft into a
human stromal cell bed which may be important for long-
term support of human stem cell function by direct phys-
ical contact or the local secretion of stromal soluble factors.
Several approaches have been tested in order to
improve the functional support of human HSPCs in
immunodeficient mice. First, human cytokines have been
directly injected to a host mouse before and after human
HSPCs injection that promoted engraftment and differ-
entiation of human cells when compared to the control
[11, 12]. Since single injection of human cytokines only
produces a transient effect, repeated injections are typ-
ically required, which is cost-prohibitive and burden-
some. Alternatively, human gene encoded lentiviral
vectors [13] or plasmid deoxyribonucleic acids (DNAs)
[14] have been applied to directly transfect host cells
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and synthesize human cytokines. Second, using gene
knock-in methods, immunodeficient mouse strains
have been generated to express human major histocom-
patibility complex (MHC) while suppressing mouse
MHC molecules that improved human immune system
development [2, 15]. Transgenic expression of human
cytokines and growth factors has been also demon-
strated to modulate human HSPCs responses [14]. For
instance, human stem cell factor, granulocyte-macrophage
colony stimulating factor and interleukin-3 genes inserted
NOD-scid IL2rγnull (NSG) mice models demonstrated
enhanced hematopoietic reconstitution of human HSPCs
[16]. Although this approach is promising, it is labor/
time-intensive, requires specialized facilities and equip-
ment, and is limited in throughput of genes expressed in a
single mouse. Moreover, ubiquitous expression of human
molecules could be problematic to interpret experimental
outcomes. Lastly, human cells and tissues can be directly
introduced into the murine host. For example, human
bone marrow stromal cells (hBMSCs) were introduced
into a mouse bone marrow cavity by intra-femoral injec-
tion. The presence of human stromal cells in a mouse
bone marrow increased engraftment of subsequently
injected human HSPCs [17]. However, this invasive pro-
cedure is compatible with only a few bones which limits
the throughput of this approach in supporting human
HSPCs function. Human fetal thymic and fetal liver
tissues, known sites of early hematopoiesis, have been
implanted in an immunodeficient mouse prior to human
HSPCs injection. A mouse carrying primary human fetal
tissue organoids demonstrated complete hematopoietic
reconstitution of human HSPCs [18]. Although this study
demonstrated the possibility to recreate a full spectrum
human hematopoietic cells in mouse models, human fetal
thymus and liver tissues are difficult to widely source mak-
ing broad adoption unattainable.
In this report, we introduce an integrated bioengin-
eering approach that can increase the throughput of
model systems research for human HSPCs by using
genetically engineered scaffold microenvironments.
Engineered stromal cells, stably synthesizing a human
cytokine or growth factor, were embedded in three-
dimensional (3D) porous hydrogel scaffolds and
implanted into immunodeficient mice in different
subcutaneous locations. Each implant created a unique
hematopoietic-supportive tissue microenvironment
over time. These implants exhibited a locally concen-
trated environment of human cells and soluble factors
with the opportunity to make multiple, autonomous
scaffolds implanted into the same mouse. We demon-
strated the engineering of stromal cells with individual
human cytokines, the control of local and systemic
exposure of engineered cytokines, and functional
characterization of the implanted microenvironments
with human HSPCs. The presented method is versatile
and can be readily applied to other human cells and
cytokines with minor modifications for better under-
standing human biology.
Methods
All chemicals and supplies were purchased from Sigma Al-
drich or Fisher Scientific unless otherwise stated. All
mouse and primary human cell experiments were reviewed
and approved by an internal review board of Massachusetts
General Hospital.
Stromal cell culture
Primary hBMSCs were isolated from healthy donor’s fresh
bone marrow (Lonza) following a previously reported
protocol [19]. Briefly, hBMSCs were cultured with medium
composed of 15 % fetal bovine serum, 100 U/mL penicillin,
100 μg/mL streptomycin, 20 mg/L gentamicin, 1 ng/L
fibroblast growth factor, and 3 g/L sodium bicarbonate in
alpha-minimum essential medium (a-MEM). Human um-
bilical vein endothelial cells (HUVECs) were purchased
from Invitrogen and cultured with medium composed of
10 % low serum growth supplement, 100 U/mL penicillin
and 100 μg/mL streptomycin. Mouse bone marrow stro-
mal cells (mBMSCs) were purchased from Invitrogen and
cultured with medium composed of 15 % fetal bovine
serum, 100 U/mL penicillin, 100 μg/mL streptomycin,
20 mg/L gentamicin, 1 ng/L fibroblast growth factor, and
3 g/L sodium bicarbonate in a-MEM. All cell cultures were
maintained at 37 °C, 5 % CO2 and 100 % humidity. Human
peripheral blood derived CD34 cells were purchased from
StemCell Technologies and after thawing immediately used
for in vivo experiments without culture.
Generation of lentiviral particles encoded human VEGFa,
SDF1a and TNFa genes
The self-inactivating lentiviral vector backbone pRRL.
PPT.SFFV.IRES.eGFP were kindly provided by Christopher
Baum (Hannover Medical School, Hannover, Germany).
cDNA clones of the human cytokines Vascular Endo-
thelial Growth Factor A (hVEGFa), Stromal Derived
Factor 1 Alpha (hSDF1a), and Tumor Necrosis Factor
Alpha (hTNFa) were purchased from Open Biosystems,
Polymerize chain reaction (PCR) amplified, and cloned
into pRRL.PPT.SFFV.IRES.eGFP. Lentiviral particles
were generated by transient calcium phosphate transfec-
tion of HEK293T cells (ATCC CRL-3216) with the lenti-
viral constructs, psPAX2 (Addgene Plasmid #12260), and
pMD2.g (VSV-G, Addgene Plasmid #12259) at the ratio 1:
2: 0.33. Viral supernatants were harvested 40 h post trans-
fection by centrifugation and stored −80 °C until use.
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Generation of genetically engineered mouse bone
marrow stromal cells
mBMSCs were plated in a 12-well plate. Once the cul-
ture reached about 50 % confluence, the medium was
replaced with 0.5 ml of new medium containing 1:10
diluted lentiviral particles and 2 μg/ml Polybrene
(Hexadimethrine bromide), and incubated for 8 h.
Afterwards the cell surface was washed with PBS three
times and 1 ml of normal medium was added in each
well. After 48 h, mBMSCs expressing green fluores-
cent protein (GFP) were sorted out using a fluores-
cence activated cell sorting (FACS) machine (BD
FACSAria II cell sorter). Expression of GFP was con-
firmed under a fluorescent microscope (Zeiss Axio
200) and secretion of hVEGFa, hSDF1a, and hTNFa
was determined by enzyme-linked immunosorbent
assay (ELISA) kits (R&D systems).
Fabrication of inverted colloidal crystal hydrogel scaffolds
and in vitro 3D stromal cell culture
Polyacrylamide hydrogel based inverted colloidal crystal
scaffolds were prepared following the previously reported
methods [20]. Final hydrogel scaffolds were consisted of
regularly arranged spherical pores (D = 250 ± 30 μm) of
which surface was coated with type I collagen utilizing
amine reactive heterbifunctional cross-linker (Sulfo-
SANPH). Dimensions of cylindrical shape hydrogel scaf-
folds were about 1.5 mm in thickness and 6.5 mm in
diameter. Prior to cell seeding, hydrogel scaffolds were
dehydrated in a laminar hood for 30 min and then a dense
genetically engineered mBMSCs or hBMSCs (0.5 × 106
cells in 40 μl) was dropped on the hydrogel scaffold. Rehy-
dration process promoted effective cell distribution into a
complex 3D porous geometry and seeded stromal cells
formed stable adhesion on collagen fiber coated pore sur-
face in 4–6 h. After 3 days culture, the level of hVEGFa,
hSDF1a, and hTNFa molecules in the medium was deter-
mined using ELISA kits. Total cell mass in each scaffold
was quantified using a MTT 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) reagent (ATCC)
and used for normalization of cytokine secretion.
In vivo microenvironments formation with genetically
engineered stromal cells
Three different stromal compositions were used for
creating subcutaneous microenvironments in single host
mouse (Table 1); (i) Growth-competent genetically engi-
neered mBMSCs (0.5 × 106 cells in 40 μl); (ii) 1:1
mixture of growth-competent genetically engineered
mBMSCs (0.25 × 106 in 20 μl) and hBMSCs (0.25 × 106
in 20 μl); (iii) Growth-arrested genetically engineered
mBMSCs (0.5 × 106 in 40 μl). Growth-arrested engi-
neered stromal cells were prepared by treating growth
competent stromal cells with 10 μg/mL mitomycine C
containing medium for 3 h. Post 3-day in vitro culture,
stromal cell-scaffolds were subdermally implanted on
the dorsal side of a 8 week-old NOD/SCID/IL2νnull
(NSG) male mouse (Jackson Laboratory) following the
previously reported method [20]. Four types of cell-
scaffolds were implanted beneath the skin of immunode-
ficient mice. A distance between implanted scaffolds was
maintained at least 2 cm in order to prevent their
contact. After 6 weeks, mice were scarified and periph-
eral blood (0.5–1 ml) and implanted scaffolds samples
were retrieved. Bloods were allowed to clot at room
temperature for 1 h, centrifuged at 6000 rpm for 10 min,
and serum was collected. The level of hVEGFa, hSDF1a,
and hTNFa molecules in serum was determined using
ELISA kits. A low level of hSDF1a was detected in
control NSG mice without carrying scaffolds due to anti-
body cross-reactivity with mouse SDF1a. This back-
ground signal was subtracted from the final data.
Explanted scaffolds were embedded in optical cutting
temperature compound, snap frozen with dry ice-chilled
2-methylbutane, and saved for histological analysis.
Systemic migration of human CD34 cells to the implanted
microenvironments
A 2:1 ratio mixture of growth-arrested genetically engi-
neered mBMSCs (0.5 × 106 in 40 μl) and hBMSCs
(0.25 × 106 in 20 μl) was introduced into a scaffold. Post
3 days in vitro culture, the cell-scaffolds were subcutane-
ously implanted into NSG mouse. After 4 weeks im-
plantation, 2.5 × 105 human CD34 (hCD34) cells were
intravenously injected. Post 24 and 72 h, mice were
sacrificed and implanted scaffolds, bone marrow and
spleen samples were collected. Hematopoietic cells were
retrieved from scaffold and tissue samples following the
previously reported method [20]. Briefly, explanted scaf-
folds were minced into small pieces (1–2 mm), incu-
bated in 2 mg/ml collagenase solution for 20 min and
thoroughly mashed using a plunger rod from a 3 ml
syringe. 40 μm cell-strainers were used to separate cells
from hydrogel scaffold and tissue debris. For bone marrow
cell isolation, tibias and femurs were dissected and the
marrow space was flushed with medium using a 23-gauge
needle. Collected marrow cells were passed through 70 μm
cell-strainers to remove bony spicules and debris and
treated with red blood cell (RBC) lysis buffer for 1–2 min.
For spleen cell isolation, a retrieved spleen was placed on a
40 μm cell-strainer and gently mashed using a plunger rod
with Rosewell Park Memorial Institute (RPMI) medium.
Harvested spleen cells were treated with RBC lysis buffer
for 2–3 min. Retrieved hematopoietic cells were stained
with fluorescein isothiocyanate (FITC) conjugated anti-
human CD34 antibody (BD Pharmingen) and analyzed
using FACS machine (BD) and FlowJo program.
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Direct implantation of human CD34 cells with
genetically engineered stromal cell-scaffolds and
ex vivo methylcellulose assay
A 2:1 ratio mixture of growth-arrested genetically engi-
neered mBMSCs (0.5 × 106 in 40 μl) and hBMSCs
(0.25 × 106 in 20 μl) was introduced into a scaffold. Post
3 days culture, cell-scaffold plates were placed in a
refrigerator for 20 min and then removed medium both
from a well and a hydrogel scaffold using a pipette. Next
ice-cold, moderately dehydrated cell-scaffolds were trans-
ferred to a 96-well plate and 50 μl of ice-cold matrigel
containing the mixture of 2 × 105 HUVECs and 2 × 105
hCD34 cells was infiltrated into the hydrogel scaffold
pores via centrifugation at 4 °C, 1500 rpm for 15 min. The
matrigel-cell filled scaffolds were incubated for 20 min at
37 °C incubator to solidify the gel and then 1 ml of culture
medium was placed in each well.
After 3 weeks in vivo implantation, hematopoietic cells
were retrieved from explanted scaffolds following the
above procedure. Hematopoietic cells were dispersed in
methylcellulose medium containing recombinant cyto-
kines and erythropoieting for human cells (MethoCult
H4034, Stem Cell Technologies). Final concentration
was 1 × 105 hematopoietic cells in 1.1 ml methylcellulose
medium that was plated in a 35 mm dish following a
protocol provided by the vendor. After 2 weeks incuba-
tion, colony forming units of (i) erythroid, (ii) granulo-
cyte and macrophage, (iii) granulocyte, erythrocyte,
monocyte and megakaryocyte, and (iv) burst forming
unit of erythroid were distinguished and counted under
an inverted light microscope.
Histological analysis
Frozen scaffold blocks were cut into 10–30 μm thickness
using a cryostat (Leica Biosystems) and stored at −80 °C
until use. For hematoxylin and eosin, and Masson’s
Trichrome staining, frozen tissue sections were fixed
with 10 % buffered formalin solution and stained following
the vendor’s protocol (American Master Tech). For im-
munofluorescence staining, frozen tissue sections were
fixed with ice-cold acetone, blocked with 10 % normal
goat serum and 1 % bovine serum albumin diluted in
phosphate buffered saline (PBS). Slides were incubated
with rat anti-mouse CD31 (BD Pharmingen) and rabbit
anti-human CD34 antibody (Abcam) for overnight. Subse-
quently the slides were stained by goat anti-rat immuno-
globulin G (IgG) conjugated with alexa fluor 488 and goat
anti-rabbit IgG conjugated with alexa fluor 568 (Invitro-
gen) for 1 h. Finally, VectaShield mounting medium with
DAPI was applied and slides were imaged under a fluores-
cence (Zeiss 200) microscope. Open source image analysis
software, ImageJ, was used to process and quantify areas
of collagen fibers and vasculatures in Masson’s Trichrome
and mouse CD31 stained slides, respectively.
Imaging
Explanted scaffolds were fixed in 2 % glutaladehyde solu-
tion for 6 h and then serially dehydrated with 20, 50, 70,
90 and 100 % ethanol solution. The scaffolds were further
dried using a lyophilzer overnight. A thin platinum/gold
coating was made on the samples using a sputter coating
machine (208HR,Cressington) and imaged under FESEM
Ultra55 (Zeiss).
Statistics
Statistical comparisons of data were per- formed using
SPSS version 17 software. Nonparametric tests, i.e.,
Kruskal-Wallis and Mann-Whitney tests, were applied
for ELISA and LSK cell analysis, respectively. Compari-
sons of human cell engraftment in long-term engraft-
ment studies were performed using an unpaired Student
t test on GraphPad PRISM version 5.
Results
Genetically engineered mouse stromal cell lines secreting
human VEGFa, SDF1a, or TNFa
In order to create a specific human soluble factor
enriched microenvironment, we first designed lentiviral
vectors that encoded human vascular endothelial growth
factor a (hVEGFa), human stromal cell derived factor-1
alpha (hSDF1a), and human tumor necrosis factor alpha
(hTNFa) genes along with enhanced green fluorescent
protein (eGFP) (Fig. 1a). A lentiviral control was also ap-
plied expressing eGFP but not a specific cytokine.
mBMSCs were infected with lentiviral particles and
sorted by FACS to purify eGFP cells. Mouse cells were
Table 1 Three stromal cell-seeding compositions for creating 4 distinct microenvironments in a mouse
Composition A Composition B Composition C
Implant site 1 Growth-competent mBMSCs
secreting hVEGFa
Growth-competent mBMSCs secreting
hVEGFa + hBMSCs
Growth-arrested mBMSCs
secreting hVEGFa
Implant site 2 Growth-competent mBMSCs
secreting hSDF1a
Growth-competent mBMSCs secreting
hSDF1a + hBMSCs
Growth-arrested mBMSCs
secreting hSDF1a
Implant site 3 Growth-competent mBMSC
ssecreting hTNFa
Growth-competent mBMSCs secreting
hTNFa + hBMSCs
Growth-arrested mBMSCs
secreting hTNFa
Implant site 4 Growth-competent mBMSCs
control
Growth-competent mBMSCs control + hBMSCs Growth-arrested mBMSC control
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used for these studies to ensure long-term survival of
engineered stromal cells because even severely immun-
compromised mice still retain immune compartments
that can detect human cells. The purified cells were
culture-expanded to establish 3 genetically engineered
mBMSC-lines i.e. mBMSC-hVEGFa, mBMSC-hSDF1a,
and mBMSC-hTNFa (Additional file 1: Figure S1).
Genetically engineered stromal cells were then seeded
into the 3D hydrogel scaffolds following the previously
reported methods [20]. These hydrogel scaffolds con-
sisted of regularly arranged spherical cavities, whereby
the cavity surfaces were coated with type I collagen. This
coating method promoted homogenous stromal cell
seeding and subsequent adhesion (Fig. 1b). The charac-
terized rate of soluble factor secretion of genetically
engineered stromal cells in the scaffolds was 4.42 ±
0.24 μg/mL for hVEGFa, 0.87 ± 0.16 μg/mL for hSDF1a,
and 2.7 ± 0.02 μg/mL for hTNFa over 3 days. When
compared to primary hBMSCs growing in the scaffolds,
normalized hVEGFa and hSDF1a secretion were about
4.8 and 3.7 folds higher, respectively (Fig. 1c-e). hBMSCs
do not naturally secrete hTNFa. These stable cell lines
were advanced for further in vivo testing.
Control of systemic and local exposure of engineered
factors after in vivo implantation
We subcutaneously implanted genetically engineered
growth-competent stromal cell seeded scaffolds into
immunodeficient NOD-scid IL2rγnull (NSG) mice and
determined whether these engineered factors could be
detected in vivo. Four different types of engineered stro-
mal cell-seeded scaffolds were implanted into a NSG
mouse (Fig. 2a). Peripheral blood samples were collected
at 6 weeks post implantation and the level of human
cytokines in serum was measured using ELISA. Detectable
levels of hVEGFa (33.93 ± 3.88 pg/ml) and hSDF1a
(238.97 ± 8.01 pg/ml) were found in peripheral blood
while there was no hTNFa. We next examined whether
systemic exposure of secreted molecules can be controlled
Fig. 1 Creating genetically engineered stromal cell-coated implantable microenvironments. a Design of lentiviral vectors encoding hVEGFa, hSDF1a,
and hTNFa genes for genetically engineered mBMSC-line generation. b Microfabricated hydrogel scaffold that represents a standardized and fully
interconnected porous microstructure (top) and a fluorescent image of genetically engineered mBMSC residing in a 3D scaffold (bottom). c-d Normalized
secretion of (c) hVEGFa, (d) hSDF1a, and (e) hTNFa from genetically engineered stromal cells for 3 days. The secretion rates were compared with hBMSC
growing in the same hydrogel scaffolds
Fig. 2 Characterization of human cytokines in peripheral blood of mice
carrying different states of genetically engineered stromal cell-laden
scaffolds. a Schematic of creating different human cytokine producing
local microenvironments beneath the skin in an immunodeficient NSG
mouse and a gross image of scaffolds after 4 weeks implantation.
b, c Detection of (b) hSDF1a and (c) hVEGFa in mouse blood
serum post 6-week implantation (N = 3–5, *P < 0.05). A low level
hSDF1a caused by cross-reactivity with mouse SDF1a was subtracted
from the data. Systemic level hSDF1a and hVEGFa were detected in
genetically engineered growing mBMSC scaffolds bearing mice but
not hTNFa. Systemic level availability of hSDF1a and hVEGFa were
significantly increased by co-seeding with hBMSC or dramatically
decreased by arresting their growth
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by manipulating the growth of genetically engineered stro-
mal cells. In our previous studies, hBMSCs accelerated
and augmented inter-scaffold angiogenic process via
secreting pro-angiogenic and immunomodulatory mole-
cules [20, 21]. To enhance the survival and systemic distri-
bution of secreted molecules, we co-seeded a 1:1 ratio
hBMSCs and engineered stromal cells into the scaffolds.
Peripheral blood analysis 6 weeks after implantation re-
vealed significantly increased level of hVEGFa and
hSDF1a, but again no hTNFa was detected. We then hy-
pothesized that systemic exposure of cytokines secreted
from the engineered stromal cells could be reduced by
limiting stromal cell proliferation. To test this hypothesis,
we treated genetically engineered stromal cells with mito-
mycine C that bound to microtubules and blocked cellular
division. Growth-arrested stromal cells remained viable
and maintained comparable levels of human cytokine
secretion during 3 weeks of in vitro culture (Additional
file 1: Figure S2). Growth arrested stromal cell-seeded
scaffolds were subdermally implanted to NSG mice and
6 weeks after peripheral blood levels of human cytokines
were measured. We confirmed the absence of hVEGFa
and hTNFa, and a lower level of hSDF1a (Fig. 2b, c). The
residual hSDF1a level was caused by cross-reactivity of the
antibody with mouse SDF1a (Additional file 1: Figure S3).
Collectively these results indicate that genetically engi-
neered stromal cells remained bioactive after in vivo
implantation. The secretion levels were controllable by
manipulating their survival and growth.
Local tissue formation in scaffolds is altered by stromal
cell proliferation
The next aspect of our study was to understand local tissue
development in scaffolds that were seeded with growth-
arrested stromal cells compared to growth-competent stro-
mal cells. Gross images of explanted scaffolds seeded with
growth-competent engineered stromal cells showed exces-
sive tissue development that completely engulfed the
implanted scaffolds except the hTNFa scaffolds (Fig. 3a, b).
On the other hand, growth-arrested stromal cell scaffolds
maintained their original dimension and showed dark red
color due to locally recruited red blood cells (Fig. 3c).
Histopathological analysis of growth-competent stromal
cell scaffolds revealed a densely populated stromal cells
and deposited extracellular matrix (ECM) with few
hematopoietic cells, while hTNFa scaffolds were mostly
filled with hematopoietic cells that mimics tissue inflam-
mation (Fig. 3d). In case of growth-arrested stromal cell
scaffolds, developed tissues were hypocellular and accom-
modating both stromal and hematopoietic components in
an organized manner. Hematopoietic cells were primarily
found at the pore surface and stromal cells were located in
the pore center. Control and hVEGFa scaffolds showed
comparable microenvironments, while hSDF1a scaffolds
exhibited significantly increased hematopoietic cells. Again
hTNFa scaffolds showed partially acellular areas with an in-
flammatory leukocyte reaction (Fig. 3e). Further SEM ana-
lysis distinguished densely filled fibroblastic tissue and
ECM in growth-competent stromal cell-scaffolds, and co-
existence of hematopoietic and stromal cells in growth-
arrested stromal cell-scaffolds (Additional file 1: Figure S4).
Implanted microenvironments support systemic
migration and retention of human CD34 cells
Having multiple, autonomous microenvironments in a
single mouse provided an opportunity to study human
HSPCs function in unique ways. In our next set of ex-
periments, we exploited growth-arrested stromal cell
scaffolds that form locally enriched human soluble mi-
croenvironments while providing room for growth of
human HSPCs. Prior to seeding growth-arrested stromal
cells were mixed with hBMSCs that improved survival of
stromal cells after in vivo implantation in the above
study (Fig. 4a). We first characterized soluble factor-
dependent tissue microenvironments focusing on inter-
scaffold ECM deposition and angiogenesis. Trichrome
staining and semi-quantitative image analysis revealed
significantly enhanced collagen deposition in control
and hVEGFa scaffolds, whereas only sparse collagen
fibers were deposited in hTNFa scaffolds reminiscence
to a necrotic tissue (Fig. 4b, c and Additional file 1:
Figures S5 and S6). Immunohistostaining of mouse
CD31 (mCD31) endothelial cells showed considerably
more blood vessels in control and hVEGFa scaffolds
than hSDF1a and hTNFa scaffolds (Fig. 4d and e).
Collectively these results indicate that growth arrested
stromal cells created a soluble factor enriched local micro-
environments that induced distinct tissue formation.
We next evaluated if human CD34 (hCD34) HSPCs
migrate to specific engineered implants in a competitive
transplantation assay. In a single mouse, 4 different types
stromal cell seeded scaffolds were implanted and ma-
tured in vivo for 4 weeks. Mice were administered 2 ×
105 hCD34 cells by intravenous injection. At 24 and
72 h post-injection, we explanted scaffolds and retrieved
hematopoietic cells to measure short-term migration of
hCD34 cells to the scaffolds (Fig. 5a). Immunohistostain-
ing of explanted scaffolds post 72 h injection confirmed
that implanted microenvironments recruited circulating
hCD34 cells. Most hCD34 cells were detected next to
the vasculature as single cells and their number was
comparable among stromal cell types (Fig. 5b). Flow
cytometric analysis quantified the percentage of mi-
grated hCD34 cells to the implanted scaffolds, which
was significantly lower when compared to the endogen-
ous bone marrow and spleen. The percentage of hCD34
cells remained the same in control and hTNFa scaffolds
and even increased in hVEGFa and hSDF1a scaffolds
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between 24 and 72 h characterization. On the other
hand, hCD34 cell number in the bone marrow and
spleen were reduced after 72 h (Fig. 5c). In general, an
implanted microenvironment recruited circulating
hCD34 cells and retained them, though differential mi-
gration to a preferential scaffold was not observed in this
model system.
Skewed in vivo differentiation of hCD34 cells in
engineered microenvironments
The soluble factors that were selected for overexpression
in stromal cells all have known effects on HSPCs migra-
tion, differentiation, and maintenance [22–24]. In this
subset study, we wanted to verify the bioactivity of these
molecules on differentiation in our model system.
Scaffolds pre-seeded with growth-arrested genetically
engineered stromal cells and hBMSCs were cultured for
3 days. On the day implantation, hCD34 cells and
HUVECs dispersed in matrigel were infiltrated into the
cavities of hydrogel scaffolds by centrifugation and then
solidified resulting in a complex 3D tissue structure that
was durable throughout the implantation procedure
(Fig. 6a). HUVECs were used to induce rapid angiogen-
esis in the implanted microenvironments for promoting
the survival of hCD34 cells since they were directly im-
planted into a non-vascularized scaffold in this study.
This tissue construct was implanted into mice at 4 dif-
ferent locations representing the one different engi-
neered soluble factor that was overexpressed. After
3 weeks of in vivo growth, the scaffolds were explanted
Fig. 3 Comparison of tissue formation between growth-competent and growth-arrested genetically engineered stromal cells seeded scaffolds. a
Gross image of explanted scaffolds with growing genetically engineered stromal cells 6 weeks after implantation, and (b) Diameters of explanted
scaffolds (N = 5, *P < 0.05). c Gross image of explanted scaffolds with growth arrested genetically engineered stromal cells 6 weeks after implantation
(Scale bar = 5 mm). d-e Comparison of hematoxylin and eosin stained tissue sections between growth-competent and growth-arrested engineered
stromal cell-seeded scaffolds. d Growth-competent stromal cells compactly filled with fibroblastic cells. e Growth-arrested stromal cells formed
organized tissue microenvironments that accommodate both stromal and hematopoietic components. Both growth competent and growth
arrested hTNFa stromal cell-scaffolds showed minimum stromal component and mimicked inflammatory microenvironment. (Scale bar, 200 μm)
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and stained for hCD34 and mCD31 expressing cells. The
results reveled that hCD34 cells were still present in the
scaffold at this time point and located in close proximity
with vasculatures in all scaffolds, except hTNFa scaffolds
(Fig. 6b). Separately, scaffold cells were retrieved and put
in a colony forming unit (CFU) assay to assess the number
of progenitor cells and their skewed differentiation poten-
tial. Isolated cells from each environment showed visual
signs of erthyroid, granulocyte, monocyte, macrophage,
and megakaryocyte by 14 days of differentiation culture in
methylcellulose with supplemented human growth factors
and cytokines. Isolated cells from each environment
showed visual signs of erthyroid, granulocyte, monocyte,
macrophage, and megakaryocyte by 14 days of differenti-
ation culture in methylcellulose with supplemented
human growth factors and cytokines (Fig. 6c). Total CFU
counting result distinguished that hSDF1a scaffolds retain
substantially higher number of hematopoietic progeni-
tor cells followed by hVEGFa scaffolds. Control and
hTNFa scaffolds accommodate comparable level, low
number of hematopoietic progenitor cells (Fig. 6d).
Further enumeration of specific colonies that were
grown from each stromal cell type, revealed a very
potent effect of hSDF1a on the maintenance of a
Fig. 4 Analysis of growth-arrested engineered stromal cell type dependent tissue microenvironments. a Schematic of experiment. Growth-arrested
genetically engineered stromal cells were co-seeded with hBMSCs into hydrogel scaffolds and subdermally implanted for 6 weeks. Explanted scaffolds
were characterized for collagen deposition and vasculature development. b Masson’s Trichrome staining visualizes collagen fibers (Blue).
c Semi-quantitative analysis of collagen deposited area (N = 6). d Immunohistostaining of mouse CD31 (green) and nucleus (DAPI) identifies
inter-scaffold vasculatures. e Semi-quantitative analysis of vasculature area (N = 6). (Scale bar, 200 μm) (*P < 0.01, **P < 0.05)
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progenitor pool in all lineages (Fig. 6e-h). Other major
notable findings were the reduction of erythroid pro-
genitors by hTNFa (Fig. 6e) and the positive effects of
hVEGFa overexpression on the number of granulocyte/
macrophage progenitor populations (Fig. 6g). The re-
sults show that this overexpression system produces
bioactive human molecules that have differentiation
effects on the human hematopoietic system as corrobo-
rated by several previous studies [25–28].
Discussion
The goal of humanized mouse models is to reconsti-
tute specific cellular and tissue dynamics to study hu-
man cell biology in vivo and potentially become a
testbed to predict human responses for precision
medicine. Studies using immunodeficient mice that
accept human cells/tissue have generally shown that by
adding complimentary human tissues, a more human-
ized response can be seen [10]. In this study, we
wanted to create a testing platform where molecules of
interest to the human hematopoietic system can be
studied in a locally enriched environment with easy ac-
cess and analytical capability. Our hypothesis was that
a single mouse can harbor multiple independent
microenvironments that have site-specific bioactivity
by implanting genetically engineered stromal cell-laden
scaffolds. Mouse cells are generally more difficult to
infect with lentivirus than human cells, though they
are more proliferative after infection and also could
survive longer after in vivo implantation than human
cells [29]. Our infection efficiency of mouse stromal
cells was ~10–30 %. The transfected cells maintained
proliferative capacity after purification by flow sorting
and expressed properly folded hVEGFa, hSDF1a, and
hTNFa. The constitutive translation of these proteins
by engineered cells was 4–5 fold more in concentra-
tion than normal hBMSCs with respect to hVEGFa and
hSDF1a. hTNFa is not naturally expressed by hBMSCs
and this construct was included to mirror an inflam-
matory reaction site. This mouse cell expression was
robust and took only a few weeks as opposed to
months/years for transgenic mice, which can further
benefit from improvement in infection efficiency while
exploring new promoter systems and unknown mole-
cules of interest to microenvironment research.
When compared to in vivo gene delivery methods that
non-specifically infect host cells to synthesize desired
human cytokines, an engineered ectopic tissue analogue
Fig. 5 Systemic recruitment of intravenously delivered hCD34 cells to the implanted tissue microenvironments. a Schematic of experimental design
for systemic migration of hCD34 cells to the different types of genetically engineered stromal cell-laden scaffolds, b Immunohistostaining of hCD34
and mCD31 cells of frozen tissue sections prepared post 72 h hCD34 cell injection. Arrows indicate hCD34 cells. (Red: hCD34, Green: mCD31 and Blue:
nucleus/Scale bars, 200 μm for upper and 50 μm for lower images) (c) Flow cytometric analysis of hCD34 cells post 24 and 72 h intravenous injection.
(N = 3, *P < 0.05)
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Fig. 6 (See legend on next page.)
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is an alternate approach with multiple advantages. First,
the porous hydrogel scaffolds were a very useful tool for
standardizing and analyzing engineered tissue microen-
vironments. The fully interconnected microscale cavities
made with a synthetic hydrogel matrix promoted angio-
genesis and, in turn, improved the survival and function
of genetically engineered stromal cells after implant-
ation. These features allowed for direct comparison of
the effects of the overexpressed gene on local tissue de-
velopment and human HSPC fate. Second, these engi-
neered tissue analogues could be studied for local or
systemic effects by simply controlling the growth poten-
tial of the engineered stromal cells. This also enables an
increase in the throughput of studies by implanting
several unique microenvironments into a single host
mouse. Finally, implanted microenvironments can ac-
commodate human HSPCs and be directly accessed for
various imaging and analytical tools [20, 30]. Thus, im-
plantable microenvironments that harbor genetically
engineered cells can broaden the study of human cells in
immunodeficient mouse models.
In our in vivo studies with engineered stromal cells,
we observed systemic levels of expressed cytokine and a
mild sarcoma-like overgrowth of these stromal cell lines
that were not under growth arrest. A typical fibroblastic
compartment is quiescent, unless the tissue bed is acti-
vated at which time the cells have been observed to pro-
liferate. The tissue cavity was not considered conducive
to support primary functions of hematopoiesis. In-
stead, a growth-arrested stromal cell population could
still express soluble, bioactive factors in an enriched
environment while allowing for additional tissue ele-
ments (e.g. hBMSCs, HUVECs, hCD34 cells) to be
included and maintain viability within the space as
seen in Fig. 5. Using growth-arrested stromal cells
eliminated systemic levels of expressed cytokines as
well. This stromal population was put on test in a
competitive transplantation assay and we did not ob-
serve site-specific homing of hCD34 cells, even to a
potent chemokine hSDF1a. The lack of a systemic che-
mokine gradient may be a plausible explanation for
non-specific homing results and can be an area of
improvement with a temporal and stronger burst of
cytokine from a non-proliferative cell mass.
The human cytokines overexpressed in our model sys-
tem, namely hVEGFa, hSDF1a, and hTNFa, were selected
based on known biological responses to hematopoietic ac-
tivity to benchmark our bioactivity studies. hVEGFa is a
potent stimulator of angiogenesis and has direct effect on
promoting the survival of HSPCs [31, 32]. hSDF1a is a
well-known chemokine molecule that actively recruits
circulating HSPCs [27, 33, 34] and maintains their activ-
ities [35]. hTNFa restricts HSPCs activity functioning as a
key precursor for inflammatory response [36, 37]. Al-
though these cytokines are designed for human specific,
evolutionary conservation of key structures and functions
in these molecules exhibited cross-reactivity with murine
tissue/cells that in turn promote distinct tissue micro-
environment formation depending on types of engineered
stromal cells. We observed sustained vascular area in
hVEGFa constructs, more cellularity and progenitor cell
activity in hSDF1a constructs, and more inflammatory cell
recruitment and collagen remodeling in hTNFa con-
structs. Our model system further reflected key biological
responses in vivo interacting with hCD34 HSPCs. This
model system can be deemed suitable to understand
short-term effects of engineered human proteins on
HSPCs function for future discovery and validation
studies. There may also be cross-reactivity of mouse
molecules on human HSPCs and vice versa, though we
maintained the same cellular composition of our scaf-
folds to control for this potential effect. A long-term
evaluation of these microenvironments is necessary to
establish true stem cell functions of serial transplant-
ation, reconstitution, and tri-lineage differentiation
after months in vivo.
Conclusion
In conclusion, we presented a bioengineering strategy to
improve humanized mouse models by creating implantable
microenvironments that release human specific cytokines
and growth factors in a controlled manner. Genetically
engineered stromal cells stably synthesize encoded human
molecules after in vivo implantation. Porous hydrogel scaf-
folds facilitated the usage of engineered stromal cells as
forming tissue-engineered depots that continuously release
engineered human molecules. Presented approach is sim-
ple and versatile that can be easily applied to other soluble
(See figure on previous page.)
Fig. 6 Analysis of soluble microenvironments dependent hCD34 cell behavior after co-implantation with hBMSCs and genetically engineered
mBMSCs. a Schematic of experimental procedure. Once hBMSCs and growth-arrested genetically engineered mBMSCs formed stable adhesion on
pore surface, the pore space was filled with hCD34 and HUVECs dispersed in liquid state ice-cold matrigel. Matrigel was subsequently solidified and hCD34
cell-retaining scaffolds were implanted to NSG mice for 3 weeks. b Immunohistostaining of explanted scaffolds post 3 weeks implantation. (Green: mCD31,
red: hCD34, and blue: nucleus/Scale bar, 200 μm). c Representative images of colony forming units after 14 days methylcellulose plating (Scale bar,
300 μm), d Compression of total CFU counting in different stromal-cell implants. e-f Comparison of specific CFU counting for differentiated
hematopoietic cell types; (e) CFU-Erythroid (CFU-E), (f) Burst Forming Unit-Erythroid (BFU-E), (g) CFU-Granulocyte and Macrophage (CFU-GM),
(h) CFU-Granulocyte, Erythrocyte, Monocyte, and Megakaryocyte (CFU-GEMM). (N = 3, *P < 0.5, **P < 0.05)
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and insoluble molecules. Combination of engineered stro-
mal cells and implantable microenvironments is expected
to be a valuable tool for generating humanized mouse
models and utilizing them for basic and translational hu-
man HSPCs as well as cancer research.
Additional file
Additional file 1: Figure S1. Selection and conformation of lentivial
transfected mouse stromal cells. (A) Flow cytometric analysis of GFP mBMSC,
(B) Culture-expanded genetically engineered mBMSCs. (Scale bar, 200μm).
Figure S2. Characterized secretion of human cytokines from genetically
engineered stromal cells in 1 and 3 weeks in vitro culture. Figure S3. hSDF1a
ELISA in mouse blood serum. Control mice without scaffold implantation
showed a background level of SDF1a signal due to cross-reactivity. This level
was used as a baseline and was also observed in growth arrested, which was
concluded, as undetectable. The other groups showed measurable levels
above background and were concluded to be true hSDF-1a detection.
Figure S4. SEM images of growth-competent genetically engineered
stromal cell-seeded scaffolds. (A) Cross-sectional images of human
soluble factor secreting engineered stromal cell-seeded scaffolds after 6
weeks subcutaneous implantation. Except hTNFa, entire pores were
completely filled with tissue cells with no hematopoietic components.
(B) Closed-up image of growing engineered stromal cell-seeded scaffolds.
Figure S5. Examples of semi-quantitative image analysis using ImageJ. (A)
Collagen fiber area estimation from a Masson’s Trichrome staining image,
(B) Vasculature area estimation from an immunohistostaining mCD31
and DAPI image. Figure S6. Long-term maintenance of inflammation-
mimicking tissue microenvironment indirectly indicates survival and
function of growth-arrested hTNFa secreting engineered stromal cells
in the implanted scaffolds. (DOCX 2962 kb)
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